$ANNX News

Citizens Upgrades Annexon to Market Perform

Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate

Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic Atrophy

Annexon Reports Early Strength Improvement And Clinically Meaningful Disability Reduction With Tanruprubart In First Ten US And European Guillain-Barré Syndrome Patients From Ongoing FORWARD Study

Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford Finance

Citizens Initiates Coverage On Annexon with Market Underperform Rating, Announces Price Target of $3

Needham Maintains Buy on Annexon, Raises Price Target to $25

Annexon Presents Data On Neuroprotective Effect Of Vonaprument At American Society Of Retina Specialists 44th Annual Scientific Meeting

Annexon: Perfect Complement To A Speculative Biotech Portfolio

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead

Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Annexon to Participate in Upcoming June Investor Conferences

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference

Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Goldman Sachs Initiates Coverage On Annexon with Neutral Rating, Announces Price Target of $7

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Q1 EPS $(0.23) Beats $(0.29) Estimate